ESSA Pharma amends Xeno deal: shareholder cash at closing reduced to ~$0.12/share from ~$1.91 estimate

ESSA Pharma Inc.

Shareholders to receive ~$0.12/share at closing (plus previously distributed $1.69) vs. originally estimated $1.91 aggregate.
CVR revised to up to ~$0.14/share, representing aggregate $6.7M contingent on liabilities.
Special meeting of shareholders further adjourned to October 3, 2025 (from Sept 29).
Amendment driven by potential liabilities, expenses, and lower estimated cash balance at closing.
XOMA Royalty continues as structuring agent and intends to provide financing.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.